Search

Displaying results 5971 - 5980 of 6198 in total
  1. Drug

    PF-03187207

    go.drugbank.com/drugs/DB05746
    Investigational

    Based on the very promising preclinical results and on the well-known activities of nitric oxide, PF-03187207 is expected to have an increased capacity to reduce high IOP.

  2. Drug

    Ticalopride

    go.drugbank.com/drugs/DB06422
    Experimental

  3. Drug

    Mito-4509

    go.drugbank.com/drugs/DB05846
    Experimental

    Mito-4509 is a non-feminizing estrogen analog that could affect mitochondrial metabolic pathways. It is used to treat Parkinson's Disease, Alzheimer's Disease, Retinal Disorders and other neurologic Disorders.

  4. Drug

    VX-148

    go.drugbank.com/drugs/DB06103
    Experimental

    VX-148 is a second-generation, orally administered inhibitor of inosine monophosphate dehydrogenase (IMPDH). The IMPDH enzyme plays a key role in regulating immune response and proliferation of specific cell types, including lymphocytes....

  5. Drug

    humanized SMART Anti-IL-12 Antibody

    go.drugbank.com/drugs/DB05848
    Experimental

    The humanized anti-IL-12 antibody is an important addition to PDL's already strong pipeline of humanized antibodies being developed for the treatment of autoimmune diseases.

  6. Drug

    8-chlorotheophylline

    go.drugbank.com/drugs/DB14132
    Experimental

    The stimulant properties of 8-chlorotheophylline are thought to ward off the drowsiness caused by diphenhydramine's anti-histamine activity in the central nervous system. 8-chlorotheophylline produces

  7. Drug

    Xaliproden

    go.drugbank.com/drugs/DB06393
    Investigational

  8. Drug

    Troxacitabine

    go.drugbank.com/drugs/DB04961
    Investigational

    Troxacitabine is a nucleoside analog with antineoplastic activity. There has been growing interest in its development for the treatment of patients with refractory lymphoproliferative conditions.

  9. Drug

    Inactivated SARS-Cov-2 Vaccine

    go.drugbank.com/drugs/DB15862
    Investigational

    Developed by Sinopharm's Wuhan Institute of Biological Products co., this vaccine consists of the WIV04 strain of SARS-CoV-2.

  10. Drug

    TMC-310911

    go.drugbank.com/drugs/DB15623
    Investigational

    [L12045,A191643] TMC-310911 is currently being investigated, in combination with other HIV therapies and antivirals, as a potential treatment for COVID-19 caused by SARS-CoV-2.[L12012]